Similarly, the RAF inhibitor sorafenib reversed memory impairment and decreased the expression of APP, Cox-2, and iNOS in the brain of an AD transgenic mouse model, highlighting the potential of targeting RAF1 [215]. This evidence concerns the gene APP and Alzheimer disease.